title: [Pharmacological approach to treatment of proliferative vitreoretinopathy].
abstract: Proliferative vitreoretinopathy (PVR) is the major cause of persistent loss of vision after retinal detachment surgery and is characterized by the formation of scar-like fibrocellular membranes on the neuroretina giving rise to tractional retinal (re-)detachment. Epithelial-mesenchymal transition, adhesion, migration and proliferation of retinal pigment epithelial (RPE) cells disseminated from the normal site at Bruch's membrane in concert with an activation of glial cells, hyalocytes and immune cells are key cellular events in the onset of the disease. The interplay between the cellular events and various growth factors, cytokines and matrix proteins thereby drives the undesirable formation of PVR membranes. Blocking these pathological events would greatly enhance the overall prognosis of surgical treatment. Clinical trials assessing the efficacy of antiproliferative and anti-inflammatory substances have yielded mixed results. Thus no safe or sufficiently effective pharmacological agent has so far been established in the clinical routine. Recent advances in the fundamental understanding of the pathogenesis of PVR aided in the identification of several new therapeutic targets to block the cellular events intrinsic to the disease. This article gives an overview of the results for adjunct therapies already tested in clinical studies and highlights experimental concepts for novel treatment strategies.
authors.affiliation: Augenklinik, AKH Linz, Linz, Deutschland, Claudia.alge-priglinger@med.uni-muenchen.de.
authors.forename: C S
authors.initials: CS
authors.lastname: Priglinger
authors.forename: S
authors.initials: S
authors.lastname: Priglinger
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000188:drug therapy*; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D009883:Ophthalmic Solutions
references.citation: Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3117-24
references.pmid: 12202537
references.citation: Arch Ophthalmol. 2007 Sep;125(9):1161-7
references.pmid: 17846353
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17504-9
references.pmid: 18952846
references.citation: Invest Ophthalmol Vis Sci. 1996 Apr;37(5):843-54
references.pmid: 8603869
references.citation: Graefes Arch Clin Exp Ophthalmol. 1999 Aug;237(8):691-6
references.pmid: 10459620
references.citation: Klin Monbl Augenheilkd. 2010 Mar;227(3):168-74
references.pmid: 20234978
references.citation: Ophthalmic Surg. 1989 Apr;20(4):268-72
references.pmid: 2733993
references.citation: Am J Pathol. 2011 Dec;179(6):2931-40
references.pmid: 22035642
references.citation: Ophthalmology. 1995 Mar;102(3):412-8
references.pmid: 7891978
references.citation: Mol Vis. 2009 Oct 23;15:2162-73
references.pmid: 19898636
references.citation: Retina. 2012 Feb;32(2):232-41
references.pmid: 21934553
references.citation: Am J Pathol. 2010 Jul;177(1):132-40
references.pmid: 20489144
references.citation: Am J Ophthalmol. 1998 Oct;126(4):550-9
references.pmid: 9780100
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1649-60
references.pmid: 21735240
references.citation: Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1305-11
references.pmid: 17325177
references.citation: Cochrane Database Syst Rev. 2013 Jan 31;(1):CD006421
references.pmid: 23440808
references.citation: Curr Eye Res. 2008 Jul;33(7):599-609
references.pmid: 18600493
references.citation: Retina. 2011 Jun;31(6):1137-42
references.pmid: 21317835
references.citation: Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2318-25
references.pmid: 8843916
references.citation: Invest Ophthalmol Vis Sci. 1995 Feb;36(2):391-405
references.pmid: 7531185
references.citation: Ophthalmology. 2001 Jul;108(7):1179-83
references.pmid: 11425671
references.citation: Br J Ophthalmol. 2004 Sep;88(9):1201-5
references.pmid: 15317716
references.citation: J Ocul Pharmacol Ther. 2008 Feb;24(1):25-33
references.pmid: 18370874
references.citation: Curr Eye Res. 1999 Oct;19(4):323-9
references.pmid: 10520228
references.citation: Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1392-7
references.pmid: 23341018
references.citation: Ophthalmology. 2004 Dec;111(12):2240-5
references.pmid: 15582080
references.citation: Graefes Arch Clin Exp Ophthalmol. 1996 Aug;234(8):496-503
references.pmid: 8858355
references.citation: Ophthalmic Surg Lasers Imaging. 2007 Jul-Aug;38(4):276-82
references.pmid: 17674917
references.citation: Ophthalmology. 2008 Nov;115(11):1938-43
references.pmid: 18584876
references.citation: Acta Ophthalmol. 2011 Sep;89(6):e505-14
references.pmid: 21457483
references.citation: Clin Exp Ophthalmol. 2002 Oct;30(5):348-51
references.pmid: 12213159
references.citation: Acta Ophthalmol Scand. 2003 Dec;81(6):663-5
references.pmid: 14641276
references.citation: Am J Ophthalmol. 2008 Sep;146(3):440-446
references.pmid: 18599016
references.citation: Ophthalmology. 1984 Feb;91(2):122-30
references.pmid: 6709326
references.citation: Am J Ophthalmol. 1987 Jul 15;104(1):10-4
references.pmid: 3605276
references.citation: Ophthalmology. 2007 Apr;114(4):698-704
references.pmid: 17398320
references.citation: Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct;38(5):365-70
references.pmid: 17955840
references.citation: Gene Ther. 2002 Sep;9(18):1214-20
references.pmid: 12215888
references.citation: Invest Ophthalmol Vis Sci. 1999 Nov;40(12):3058-62
references.pmid: 10549674
references.citation: Biochimie. 2011 Mar;93(3):477-88
references.pmid: 21094672
references.citation: Graefes Arch Clin Exp Ophthalmol. 1991;229(2):150-2
references.pmid: 2044976
references.citation: Lab Invest. 2005 Jul;85(7):838-50
references.pmid: 15924151
references.citation: Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1028-35
references.pmid: 19815730